Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

被引：36

作者：

Kawagishi, Naoki ^{[1
]}

Suda, Goki ^{[1
]}

Nakamura, Akinobu ^{[2
,3
]}

Kimura, Megumi ^{[1
]}

Maehara, Osamu ^{[1
]}

Suzuki, Kazuharu ^{[1
]}

Nakamura, Akihisa ^{[1
]}

Ohara, Masatsugu ^{[1
]}

Izumi, Takaaki ^{[1
]}

Umemura, Machiko ^{[1
]}

Nakai, Masato ^{[1
]}

Sho, Takuya ^{[1
]}

Natsuizaka, Mitsuteru ^{[1
]}

Morikawa, Kenichi ^{[1
]}

Ogawa, Koji ^{[1
]}

Kudo, Yusuke ^{[4
]}

Nishida, Mutsumi ^{[4
]}

Miyoshi, Hideaki ^{[3
,5
]}

Sakamoto, Naoya ^{[1
]}

机构：

[1] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[2] Hokkaido Univ, Grad Sch Med, Fac Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[4] Hokkaido Univ Hosp, Div Lab & Transfus Med, Sapporo, Hokkaido, Japan

[5] Hokkaido Univ, Fac Med, Div Diabet & Obes, Sapporo, Hokkaido, Japan

来源：

PLOS ONE | 2018年 / 13卷 / 12期

基金：

日本学术振兴会;

关键词：

HEPATITIS-C-VIRUS; METABOLISM-ASSOCIATED GENES; HEPATOCELLULAR-CARCINOMA; LIPID-METABOLISM; OXIDATIVE STRESS; DISEASE; CHOLESTEROL; EXPRESSION; THERAPY; DACLATASVIR;

D O I：

10.1371/journal.pone.0209615

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Aim We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. Methods Patients treated with IFN-free-DAAs who underwent transient elastography before and at 24-weeks post-treatment, including controlled attenuation parameter (CAP), and achieved sustained viral response (SVR) were enrolled. The association between changes in liver steatosis, lipid-metabolism, and genetic and clinical factors was analyzed. Results A total of 117 patients were included. The mean CAP and low-density lipoprotein cholesterol (LDL-C) levels were significantly elevated at SVR24. However, baseline LDL-C and CAP values were significantly negatively correlated with changes in these values after HCV eradication, indicating that in patients with high baseline values, the values generally decreased after HCV eradication. Mean small-dense LDL-C (sdLDL-C), which has greater atherogenic potential, was significantly elevated only in patients with both dyslipidemia (LDL-C > 140 mg/dL) and liver steatosis (CAP > 248 dB/m) at SVR24. Those patients had significant higher baseline BMI, LDL-C, and total-cholesterol levels. Conclusions Generally, successful HCV eradication by IFN-free-DAAs decreases CAP and LDL-C in patients with high baseline values. However, elevated LDL-C was accompanied with elevated sdLDL-C only in patients with liver steatosis and dyslipidemia at SVR24; therefore, those patients may require closer monitoring.

引用

页数：17